Argo Biopharma is a clinical stage biotech company that committed to developing a new generation of siRNA drugs to provide better treatments for global patients.
Learn More2021
Company EstablishedOver US $100 M
Closed Financing90 +
Employees29
PCT Patent Submitted30 +
Pipelines5
Clinical-stage AssetsArgo Biopharma specializes in siRNA drug discovery and development. Our industry-leading siRNA platform technology, RADS (RNA molecules with superior Activity, Durability, and Safety), is the cornerstone of our innovative approach.Based on this platform, the drugs have the potential to achieve the goal of one injection per year in clinical practice for certain indications.
Learn MoreAs a platform company, Argo Biopharma has a rich portfolio of product pipelines covering a wide range of indications, including cardiovascular diseases, rare diseases, CNS disorders, viral hepatitis, metabolic conditions, and more.
Learn MoreWith its cutting-edge siRNA platform technology, RADS, Argo Biopharma is able to provide Best-In-Class candidates for a range of indications.
Argo's extensive pipeline encompasses a wide range of therapeutic areas, including cardiovascular, metabolic disorders, hematological, CNS, hepatitis, and complement mediated diseases. We recognize that collaborating with other organizations can expedite the advancement of our novel medications towards clinical trials and eventual commercialization. To expand our wide pipelines, we are open to out-licensing, asset acquisitions, and strategic partnerships.
Argo Biopharma Announces Completion of First Participant Dosing in China Phase I Clinical Study of BW-03, a Novel RNAi Therapeutics for the Treatment of CHB
Learn MoreFirst Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia
Argo Biopharma has completed phase 1 clinical trials for BW-01, a siRNA candidate for cardiovascular diseases, in China and Australia.
Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis.
为了更好的呈现效果，移动端请竖屏浏览
